about-me variable
SafeBiologics and GaBI invites you to their event

NON-MEDICAL SWITCHING OF BIOLOGICALS/ BIOSIMILARS: CANADA, EUROPE AND THE US

About this event

NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US

Overview of Non-Medical Switching Practices of Biologicals/Biosimilars in Different Regions and the Importance of Safeguarding the Physician–Patient Relationship
Wednesday, 20 July 2022 | 10:00 am – 12:00 pm (EDT)
Online event hosted by the Alliance For Safe Biologic Medicines and Generics and Biosimilars Initiative

The advent of biologicals offers significant benefits and enhanced quality of life for patients with chronic diseases, such as rheumatoid arthritis, multiple sclerosis and cancer. However, finding a working treatment regimen may take a long time and involves trial and error for a patient’s individual case.

Nevertheless, government policies that force biosimilar switching for non-medical and strictly economic reasons may ultimately affect patients’ treatment and their well-being, create mistrust in the healthcare system, undermine competition, increase total healthcare costs, and act as a barrier to innovation and future access to new biological drugs for patients.

Non-medical switching should consider two governing principles: 1) the physician–patient relationship must be protected to ensure the best outcomes; and 2) patients stabilized on a biological therapy should not be forced to undergo a non-medical switch.

Academic clinicians with specialties in oncology and ophthalmology, patient advocates, policymakers and regulatory experts from Canada and the US will share their experience and knowledge on medical switching and principles and guidance on interchangeability of biologicals/biosimilars, highlighting the specific concerns on, and the importance of a multi-stakeholder approach protecting the physician–patient relationship in the practice of non-medical switching of biologicals/biosimilars.

Improved information and protecting the physician–patient relationship in medical switching of biologicals/biosimilars will encourage smooth uptake of biosimilars.

Moderator:

Steve Stranne, MD, JD, Foley Hoag LLP

Speakers

Michael S Reilly, Esq, Executive Director, Alliance for Safe Biologic Medicines, USA

Gail Attara, President & CEO, Gastrointestinal Society, Canada

Ralph McKibbin, MD, FACP, FACG, AGAF, President of the Pennsylvania Society of Gastroenterology and the Digestive Disease National Coalition, USA

Leah Christl, PhD, Executive Director, Global Regulatory and R & D Policy, Amgen, USA

Durhane Wong-Rieger, PhD, President & CEO, Canadian Organization for Rare Disorders, Canada

Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, The Ohio State University

Panelists

Jaymee Maaghop, Gastrointestinal Society, Canada

Urvashi Rathod, International Federation on Ageing, Canada

To find out more about the webinar, click here to download the agenda

Don't miss out on this second ASBM/GaBI biosimilars event, REGISTER NOW!

For more information, email us at editorial@gabi-journal.net.

Hosted by

  • Guest speaker
    G
    Philip Schneider Professor @ The Ohio State University

  • Guest speaker
    G
    Durhane Wong-Rieger President & CEO @ Canadian Organization for Rare Disorders

  • Guest speaker
    G
    Ralph McKibbin President @ Blair Gastroenterology Associates

  • Team member
    T
    SafeBiologics and GaBI 2022 Webinar Program Committee

  • Guest speaker
    G
    Urvashi Rathod N/A @ N/A

  • Guest speaker
    G
    Steven Stranne, MD, JD Partner @ FOLEY HOAG LLP

  • Guest speaker
    G
    Jaymee Maaghop Outreach Coordinator @ Gastrointestinal Society

  • Guest speaker
    G
    Leah Christl Executive Director, Global Regulatory and R&D Policy @ Amgen

  • Guest speaker
    G
    Michael S Reilly, Esq Executive Director @ Alliance for Safe Biologic Medicines

  • Guest speaker
    G
    Gail Attara President & Chief Executive Officer @ Gastrointestinal Society

SafeBiologics and GaBI

Building trust in cost-effective treatments

The mission of GaBI is to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care.